BibTex format
@inproceedings{Delimpasi:2018:10.1200/JCO.2018.36.15_suppl.TPS8056,
author = {Delimpasi, S and Pour, L and Auner, HW and Dimopoulos, MA and Rappaport, A and Fortin, L and Shah, JJ and Shacham, S and Kauffman, MG},
doi = {10.1200/JCO.2018.36.15_suppl.TPS8056},
publisher = {LIPPINCOTT WILLIAMS & WILKINS},
title = {A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).},
url = {http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS8056},
year = {2018}
}
RIS format (EndNote, RefMan)
TY - CPAPER
AU - Delimpasi,S
AU - Pour,L
AU - Auner,HW
AU - Dimopoulos,MA
AU - Rappaport,A
AU - Fortin,L
AU - Shah,JJ
AU - Shacham,S
AU - Kauffman,MG
DO - 10.1200/JCO.2018.36.15_suppl.TPS8056
PB - LIPPINCOTT WILLIAMS & WILKINS
PY - 2018///
SN - 0732-183X
TI - A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
UR - http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS8056
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000442916007727&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER -